UroGen Pharma (URGN) AGM 2026 summary

Opening remarks and agenda

• The meeting was called to order by the CEO, who welcomed shareholders and outlined the agenda, including a Q&A session at the end.

• The CEO introduced the management team, legal counsel, and the Inspector of Elections, and confirmed the meeting was held virtually.

Financial performance review

• Highlighted the successful launch of ZUSDURI, the first FDA-approved treatment for a specific type of bladder cancer, with strong early adoption.

• Noted continued growth of JELMYTO and advancement of next-generation pipeline products, including UGN-103, UGN-104, and UGN-501.

Board and executive committee updates

• Seven directors were nominated for election to serve until the 2027 annual meeting.